Belluscura (FRA:9VQ) Debt-to-Revenue : 0.00 (As of Jun. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Belluscura Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Belluscura's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2023 was €0.00 Mil. Belluscura's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2023 was €0.00 Mil. Belluscura's annualized Revenue for the quarter that ended in Jun. 2023 was €0.68 Mil. Belluscura's annualized Debt-to-Revenue for the quarter that ended in Jun. 2023 was 0.00.

Belluscura Debt-to-Revenue Historical Data

The historical data trend for Belluscura's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Belluscura Debt-to-Revenue Chart

Belluscura Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Debt-to-Revenue

3.86

N/A

0.88

0.24

Belluscura Semi-Annual Data
	Dec18	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23
Debt-to-Revenue	Get a 7-Day Free Trial				N/A	0.44	-	0.20	-

Competitive Comparison of Belluscura's Debt-to-Revenue

For the Medical Devices subindustry, Belluscura's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Belluscura's Debt-to-Revenue Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Belluscura's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Belluscura's Debt-to-Revenue falls into.

Belluscura Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Belluscura's Debt-to-Revenue for the fiscal year that ended in Dec. 2022 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(0.123	+	0.189)	/	1.32
	=	0.24

Belluscura's annualized Debt-to-Revenue for the quarter that ended in Jun. 2023 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(0	+	0)	/	0.676
	=	0.00

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is two times the quarterly (Jun. 2023) Revenue data.

Belluscura Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Belluscura's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Belluscura (FRA:9VQ) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Belluscura PLC (FRA:9VQ) » Definitions » Debt-to-Revenue

Comparable Companies

Traded in Other Exchanges

BELL:UK

Address

15 Fetter Lane, Holborn, London, GBR, EC4A 1BW

Website

https://www.belluscura.com

Belluscura PLC is a medical device company. Its first product, the X-PLOR, is a lightweight FDA-cleared portable oxygen concentrator designed to replace larger, metal oxygen tanks and heavier portable oxygen concentrator devices. The X-PLO2R weighs less than 1.5kg (3.25 lbs) and it is the first modular portable oxygen concentrator it will generate more oxygen by weight than any other FDA-cleared POC in its class. It either owns or exclusively licenses a total of 26 patents and applications relating to oxygen enrichment devices and treatments.

Belluscura (FRA:9VQ) Headlines

No Headlines